Piper Sandler Raises DexCom Price Target to $88, Maintains Overweight

Piper Sandler analyst Matt O'Brien raised the firm's price target on DexCom (NASDAQ:DXCM) to $88 from $75 on June 15, 2026, while maintaining an Overweight rating on the shares. The revised target implies an upside of approximately 17% from the stock's prior closing price, signaling the analyst's bullish outlook on the continuous glucose monitoring (CGM) leader. The Overweight rating suggests that Piper Sandler expects DexCom to outperform its sector peers over the next 12 to 18 months, a view that aligns with the firm's updated financial models.

The upgrade reflects Piper Sandler's updated models to better align with quarterly cadence, company guidance, and consensus estimates. For DexCom, the firm cited greater visibility into the long-term pipeline and catalyst cadence supporting sustained, outsized top-line growth. The U.S. Food and Drug Administration recently cleared DexCom's Stelo Glucose Biosensor System for marketing, adding to the positive sentiment. Stelo is designed for non-insulin-using type 2 diabetes patients, expanding DexCom's addressable market beyond its traditional insulin-dependent user base. This regulatory win, combined with the company's robust product pipeline, underpins the analyst's confidence in DexCom's ability to capture market share in the growing CGM space. Traders tracking medical device stocks can monitor live DexCom prices and charts on NowPrice to see how the market reacts to analyst upgrades and regulatory approvals.

Investors will watch for upcoming quarterly results and any further FDA clearances for DexCom's product pipeline. The raised target suggests confidence in DexCom's ability to maintain its growth trajectory in the continuous glucose monitoring market, which remains competitive with players like Abbott and Medtronic. Key catalysts include the potential approval of DexCom's next-generation G7 sensor and expansion into international markets. Additionally, reimbursement updates from Medicare and private insurers could significantly impact adoption rates. As the CGM market evolves, DexCom's innovation and regulatory successes will be critical in sustaining its competitive edge and justifying the elevated price target.